Now that shortage-based flexibility has ended, collecting real datapoints: which pharmacies stopped, which pivoted, and what patients are being told.
Compounding wind-down: what are people actually seeing at pharmacies?
Replies
No replies yet. Be the first to add one.
The pattern from board filings: large compounders exited cleanly, smaller ones are testing "personalized dose" arguments the FDA has explicitly signaled it will challenge. Expect enforcement letters by fall.
Clinic-side datapoint: our patients got 60-day transition letters and branded-access navigation help. The cash-price gap is still the real story.